Artiva 10-Q: $319M Cash After AlloNK Wind-Down, $27-35M Restructuring Costs
ARTV sits 43% above its 52-week low of $2.96.
Summary
Artiva reported a $77.3 million nine-month net loss and $319.1 million in cash after discontinuing AlloNK, with $27-35 million of wind-down costs and a 94% workforce cut as it explores strategic alternatives.
Key Events · Earnings and Guidance · ARTV
-
AlloNK Wind-Down Quantified
On October 22, 2026, the board approved discontinuing AlloNK development and a 94% workforce reduction. The company estimates $10-15 million in contract termination and trial close-out costs plus $17-20 million in severance and related costs, mostly in Q4 2026.
-
Nine-Month Loss Widens to $77.3M
Net loss was $77.3 million for the nine months ended September 30, 2026, versus $63.1 million a year earlier, driven by R&D of $67.2 million (up from $52.5 million) as AlloNK spending peaked before the wind-down.
-
Cash Covers At Least 12 Months
Cash, cash equivalents and short-term investments totaled $319.1 million at September 30, 2026, which management says funds planned operations for at least one year from the filing date.
-
ATM Upsized to $100M
The Leerink at-the-market sales agreement was amended in August 2026 to raise the aggregate offering capacity from $11,950,000 to $100,000,000; no shares were sold under the program during the three and nine months ended September 30, 2026.
Analysis · ARTV · Life Sciences
Artiva's first full quarterly report since killing its lead AlloNK program puts numbers on the retreat: a $77.3 million nine-month net loss and $319.1 million in cash and investments, against $27-35 million of wind-down costs ($10-15 million trial close-out plus $17-20 million severance for a 94% workforce cut). Management says that cash funds planned operations for at least 12 months, so the story now is what a strategic-alternatives process yields — a sale, licensing deal or liquidation — not clinical progress. The August 2026 upsizing of the at-the-market program to $100 million is a standing dilution backstop, though no shares were sold under it in the period.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARTV was trading at $4.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $206.3M. The 52-week trading range was $2.96 to $14.53. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.